Immuron Board Changes
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Vaccine
Immuron CEO Steven Lydeamore to present at Peak Sky High
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens...
Rapid Dose Therapeutics Commits to NFL-Funded Clinical Trial Application
Burlington, Ontario--(Newsfile Corp. - May 29, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces its...
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the...
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology Paris,...
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa,...
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strainStudy initiated...
CytoDyn to Host Webcast to Provide Company Update
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...
Evaxion Announces Business Update and First Quarter 2024 Financial Results
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio...
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response...
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted...
NanoViricides Bolsters Partnership Efforts – Engages Aagami Inc.
SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in...
IO Biotech to Present at Jefferies Global Healthcare Conference
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic...
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical...
Rapid Dose Therapeutics and McMaster University’s Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery
Burlington, Ontario--(Newsfile Corp. - May 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") trading on...
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
PRINCETON, NJ / ACCESSWIRE / May 22, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage...
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDTCAMBRIDGE, MA / ACCESSWIRE /...
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher...
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20,...